期刊
CANCER PREVENTION RESEARCH
卷 12, 期 10, 页码 689-699出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1940-6207.CAPR-19-0185
关键词
-
类别
资金
- National Institute of Child Health and Human Development [R35DE026631]
- Johns Hopkins University Bloomberg School of Public Health [U01-AI35042]
- Northwestern University [U01-AI35039]
- University of California, Los Angeles [U01-AI35040]
- University of Pittsburgh [U01-AI35041]
- Center for Analysis and Management of MACS, Johns Hopkins University Bloomberg School of Public Health [UM1-AI35043]
- UAB-MS WIHS [U01-AI-103401]
- Atlanta WIHS [U01-AI-103408]
- Bronx WIHS [U01-AI-035004]
- Brooklyn WIHS [U01-AI-031834]
- Chicago WIHS [U01-AI-034993]
- Metropolitan Washington WIHS [U01-AI-034994]
- Miami WIHS [U01-AI-103397]
- UNC WIHS [U01-AI-103390]
- Connie Wofsy Women's HIV Study, Northern California [U01-AI-034989]
- WIHS Data Management and Analysis Center
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Cancer Institute (NCI)
- National Institute on Drug Abuse (NIDA)
- National Institute of Mental Health (NIMH)
- Eunice Kennedy Shriver NICHD
Performance of commercially available human papillomavirus (HPV) assays (approved for cervical HPV detection) is unknown for detecting HPV-related oropharyngeal cancer (HPV-OPC). Assays for detection of HPV DNA [ELISA (DEIA) and Cobas], and RNA (Aptima) in oral rinse samples, and serum HPV oncogene antibodies were evaluated. Sensitivity and specificity of each test was explored among HPV-OPC cases and controls. Biomarker prevalence was evaluated among 294 at-risk people (screening) and 133 high-risk people 'known to previously have oral oncogenic HPV (oncHPV) DNA and/or HPV16 E6/E7 antibodies detected]. HPV16 E6 antibodies had the best overall test performance with sensitivity of 88%, compared with oral HPV16 DNA sensitivity of 51% by DEIA and 43% by Cobas (each P < 0.001). Specificity was comparable in each of these tests (>= 98%). When positivity for any oncHPV type was compared with HPV16 for the same test, sensitivity was comparable (60% vs. 51%, 40% vs. 43%, and 92% vs. 88% for DEIA, Cobas, and E6 antibodies, respectively), but specificity was reduced (93%-97%). Aptima had poor sensitivity (23%). Sensitivity decreased when cotesting HPV16 oral rinse DNA and E6 antibodies (37%48%), or multiple E antibodies (69%-72%). HPV16 DNA were detected in similar to 2% of the at-risk by either DEIA or Cobas and up to 15% of the high-risk population. HPV16 E6 seroprevalence was 2.3% and 2.4% in the at-risk and high-risk populations, respectively. Oral rinse HPV testing had moderate-to-poor sensitivity for HPV-OPC, suggesting many true positives would be missed in a potential screening scenario. HPV16 E6 serum antibody was the most promising biomarker evaluated.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据